Ultra-Broadband Micromechanical Ultrasound (UMUS) as a Strategy to Correct Cyclophosphamide-Induced Myelosuppression Without Limiting Antitumor Efficacy.

BACKGROUND/AIMS: This study aimed to apply ultra-broadband micromechanical ultrasound (UMUS) for correction of myelosuppression caused by the cytotoxic effects of cyclophosphamide without limiting its antitumor efficacy.

METHODS

The study included animals bearing transplanted Ehrlich carcinoma. Cyclophosphamide (CP) was administered once daily for three consecutive days starting on day 8 of tumor growth at a cumulative dose of 330 mg/kg per mouse. After completion of CP administration, a subset of animals was exposed to UMUS irradiation once daily for five days. Control groups included mice without tumors and tumor-bearing mice not exposed to CP or UMUS. Tumor growth kinetics were analyzed, and quantitative parameters of peripheral blood, bone marrow, and spleen were determined.

RESULTS

The obtained data indicate that UMUS exposure does not reduce the antitumor efficacy of CP but is associated with enhanced recovery of the hematopoietic system and exerts a positive effect on bone marrow regeneration. This is confirmed by a statistically significant increase in the number of cells in specific bone marrow hematopoietic pools, including myelokaryocytes, blast cells, erythroid, lymphoid, and megakaryocytic cells.

CONCLUSION

UMUS exposure was associated with accelerated recovery of multiple hematopoietic lineages in the bone marrow following cyclophosphamide-induced injury, without compromising antitumor efficacy.